Xenitra’s pharmaceutical strategy is to connect trusted international medicine and healthcare brands with Chinese consumers. Source Adobe Stock.
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • $100 million three-year sales target, Xenitra’s largest strategic agreement to date
  • Marks major move into higher margin, regulated products with indicative prescription medicine
  • Strategic agreement at platform level with JD Health
  • Agreement will focus on prescription medicines and includes OTC medicines

Xenitra’s (ASX:XEN) prescription pharmaceutical subsidiary Shengdi Pharmaceutical has entered into a three-year strategic cooperation agreement with China’s largest online healthcare platform, JD Health International.

The Watchlist — short video interviews with ASX leaders. Watch now.

The agreement establishes an $100 million sales cooperation target over three years for internationally sourced prescription medicines, over-the-counter (OTC) medicines, Foods for Special Medical Purposes (FSMP) and health products.

Zhong Shan Kang, overseas medicines category manager at JD Health, said the agreement provides a platform-level route to market that complements Xenitra’s existing wholesale, third-party distribution and owned digital storefront channels.

“Xenitra is the first company in JD’s history to become our strategic partner without having first worked with JD Self-Operated business on healthcare products, which speaks to the trust and support our senior leadership places in Xenitra. I hope our two teams can complete the alignment and integration process and move to close the first order — within the next two weeks,” he said.

Non-executive chairman, Dr Anthony Noble, said this is the most significant commercial partnership to date for Xenitra.

“We have now assembled the licenses, international sourcing relationships, distribution infrastructure and people to build a substantial and scalable pharmaceuticals business in China.

“A direct strategic relationship with China’s largest online healthcare platform is a critical building block in delivering our vision to become a bridge for international pharmaceutical brands and consumers in Asia. The $100 million cooperation target demonstrates the scale of this market. Our immediate focus is to turn this agreement into sales of an expanded range of products, repeat orders and sustainable shareholder value.”

Dr Noble said Xenitra’s pharmaceutical strategy is to connect trusted international medicine and healthcare brands with Chinese consumers through international sourcing, licensed operations, regulatory capabilities, warehousing, logistics and established digital sales channels.

The commercial arrangements align with three distinct but complementary categories within Xenitra’s Pharmaceuticals business.

• Prescription medicines: The $100 million JD Health cooperation framework adds a significant prescription medicine opportunity and a direct platform-level relationship. This broadens Xenitra’s addressable product range and creates an additional route to market alongside existing OTC and FSMP activities.

• OTC medicines: The $12 million Kangsheng arrangement provides a procurement pathway for OTC medicines and related products. This category builds on Fukang’s established cross-border OTC operating platform and online storefront capability.

• Food for Special Medical Purposes: The $5 million Joy Charm agreement extends the offering into Foods for Special Medical Purposes, using the same sourcing, logistics and commercial platform while broadening the healthcare product mix.

XEN was steady at 0.3¢ with a Mkt cap of $12.83M prior to markets opening.

Join the discussion: See what HotCopper users are saying about Xenitra and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

xen by the numbers
More From The Market Online

Black Horse Mining intersects “Coopers Load” position with deepest hole at Mt Egerton

Black Horse Mining has obtained significant information with the successful completion of the first hole of…
The Market Online Video

Market Open: ASX faces another test as Wall Street sell-off deepens

Australian shares are heading for another difficult session today, with ASX 200 futures pointing to a fall of around 0.6% as global investors...
The Market Online Video

Market Close: ASX slides as resources and miners lead broad market sell-off

The Australian sharemarket came under renewed pressure on Tuesday 17th Nov, with selling extending across almost every sector as resources and energy

Mayne Pharma agrees to $604m takeover as Gedeon Richter offers 99% premium to shareholders

Mayne Pharma has agreed to a $604 million takeover by Gedeon Richter, offering shareholders $6.40 per…